(Total Views: 988)
Posted On: 07/30/2020 5:04:47 PM
Post# of 153908
In my opinion the news was huge. Up to now many drugs have failed in clinic trials vs. placebo for COVID-19. It is a very difficult problem.
We now have verbal verification that the drug is efficacious against a placebo for multiple endpoints. Imo, the risk of holding the stock was just reduced big time. News should be positive going forward as results are released.
These efficacy results bode well for CD12 vs. placebo.
Also, now having efficacy in HIV and COVID increases the odds (imo) of the drug working for other indications. It does appear Leronlimab is a wonder drug for multiple indications and an unprecedented safety profile. I keep saying to myself it appears too good to be true ...
We now have verbal verification that the drug is efficacious against a placebo for multiple endpoints. Imo, the risk of holding the stock was just reduced big time. News should be positive going forward as results are released.
These efficacy results bode well for CD12 vs. placebo.
Also, now having efficacy in HIV and COVID increases the odds (imo) of the drug working for other indications. It does appear Leronlimab is a wonder drug for multiple indications and an unprecedented safety profile. I keep saying to myself it appears too good to be true ...
(10)
(0)
